ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equ... (rinarymedicine for the development of in...)

ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health

Date:2/27/2008

rinary medicine for the development of innovative therapies for treatment of injuries and disease in animals," noted Dr. William Osgood, Chief Executive Officer of ThermoGenesis.

"The risk of orthopedic injury to these high-value horses and their racing careers is well known. The potential for the use of stem cells to treat these debilitating, and often life-threatening, injuries is significant and we look forward to working with UC Davis on creating new forms of therapy for these horses," he added.

"The opportunities for stem-cell based therapies are significant and being proven every day. Leading veterinarians are now using stem cells in a variety of clinical conditions and the outcomes are very encouraging. We look forward to partnering with Vantus on the advancement of scientific discoveries and breakthroughs in this area," said Dr. Gregory Ferraro of the UC Davis Center for Equine Health.

"This is a market opportunity with great potential and we believe our clinically proven stem cell processing and cryopreservation technologies coupled with the research we are funding at the UC Davis Center for Equine Health can provide us important competitive advantages. Stem cell therapies are working and the regulatory hurdles in the veterinary medicine are relatively low. As a result, we are well-positioned to realize rapid growth in this business and make it an important contributor to shareholder value. In addition, we look forward to translating the lessons learned in the equine market to stem cell-based therapies for orthopedic injuries in humans so as to expand our presence in that market as well," Osgood noted.

Four leading clinicians from UC Davis will direct the collaboration with Vantus. They include:

-- Gregory L. Ferraro, DVM has been the Director of the Center for Equine

Health, at the UC Davis, School of Veterinary Medicine since 1998.

Prior to his full time university appointment he was engaged in p
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
6. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
7. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
8. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
9. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
10. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
11. AMDLs Chinese Subsidiary Wins Key Brand Excellence Award for Anti-Aging Treatment

Post Your Comments:

ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equ...(rinarymedicine for the development of in...)